Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis.

RSS de esta página

PubMed ID: 26687352

Imagen Publicación

Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, Gu X, Huang Y, Zamanian-Daryoush M, Culley MK, DiDonato AJ, Fu X, Hazen JE, Krajcik D, DiDonato JA, Lusis AJ, Hazen SL

Cell. Dec 2015. doi: 10.1016/j.cell.2015.11.055S0092-8674(15)01574-3

COMMENT: Trimethylamine (TMA) N-oxide (TMAO) is a metabolite that depends on gut microbiome and has been related to atherosclerosis in animal models. It is also considered a risk factor for humans.

In this article the authors investigate the possibilities of inhibiting TMA production by gut microbes. They used a structural analog of choline, 3,3-dimethyl-1-butanol (DMB) and find that this compound inhibits TMA production in vitro and reduce TMAO levels in mice fed a high-choline or L-carnitine diet in vivo.

Finally, they suggest that targeted inhibition of TMA production by gut microbes may be in the future a new therapeutic approach.


Raquel Tobes